Home › Funds › Caligan Partners LP › IMCR
Caligan Partners LP position in IMCR
IMMUNOCORE HLDGS PLC · Health Care
Caligan Partners LP reported holding 1,672,141 shares of IMCR (IMMUNOCORE HLDGS PLC) in its Q3 2026 13F filing — a position valued at US$50.6M, representing 3.10% of its reported portfolio and ranking #9 among its reported holdings. Caligan Partners LP has disclosed IMCR holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Caligan Partners LP's IMCR position evolved
Caligan Partners LP first disclosed a stake in IMCR in Q2 2026 at 1,381,317 shares (US$43.9M). The position peaked in Q3 2026 at 1,672,141 shares, worth US$50.6M. Across 2 filings, Caligan Partners LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 1,672,141 shares valued at US$50.6M — an increase of 290,824 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 1.38M | $43.86M | New |
| Q3 2026 | 1.67M | $50.65M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About IMCR and 13F data
IMCR (IMMUNOCORE HLDGS PLC) is a Health Care company. 27 other funds we track also report a position in IMCR — the largest reported positions include RTW INVESTMENTS, LP (US$147.5M), TANG CAPITAL MANAGEMENT LLC (US$87.4M), Bellevue Group AG (US$68.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding IMCR
- RTW INVESTMENTS, LP 4.87M sh · $147.51M · Q3 2026
- TANG CAPITAL MANAGEMENT LLC 2.88M sh · $87.36M · Q3 2026
- Bellevue Group AG 2.26M sh · $68.59M · Q3 2026
- Kynam Capital Management, LP 1.38M sh · $41.65M · Q3 2026
- BVF INC/IL 1.23M sh · $37.28M · Q3 2026
- MPM BioImpact LLC 1.20M sh · $36.45M · Q3 2026
- ARMISTICE CAPITAL, LLC 1.14M sh · $34.41M · Q3 2026
- Trails Edge Capital Partners, LP 1.06M sh · $32.21M · Q3 2026
- FARALLON CAPITAL MANAGEMENT, L.L.C. 928.00K sh · $28.11M · Q3 2026
- BRAIDWELL LP 906.12K sh · $27.45M · Q3 2026
- Vestal Point Capital, LP 850.00K sh · $25.75M · Q3 2026
- Frazier Life Sciences Management, L.P. 829.75K sh · $25.13M · Q3 2026
More on Caligan Partners LP
FAQ
How long has Caligan Partners LP held IMCR?
Caligan Partners LP has disclosed IMCR holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is Caligan Partners LP's current position in IMCR?
As of Q3 2026, Caligan Partners LP holds 1.67M shares of IMCR (IMMUNOCORE HLDGS PLC), valued at $50.65M, representing 3.10% of its reported portfolio and ranking #9.
Has Caligan Partners LP been buying or selling IMCR?
In the latest 13F filing (Q3 2026), Caligan Partners LP increased its position in IMCR. The position peaked in Q3 2026 at 1.67M shares.
Which other funds hold IMCR?
Other major institutional holders of IMCR include RTW INVESTMENTS, LP, TANG CAPITAL MANAGEMENT LLC, Bellevue Group AG, among 27 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.